louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06279416: Expected Difficult Airway Management
Official title: Evaluation of Advanced Airway Methods Applied to Patients Who Were Awakened Due to Difficult Airway in Another Center or Who Were Predicted to Have Difficult Airway in Preoperative Evaluation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Awake Intubation
Advanced Airway Techniques
Keywords: videolaryngoscopy
fiberoptic bronchoscope
supraglottic airway device
Lead sponsor: Kocaeli City Hospital
Sponsor class: OTHER_GOV
First posted: 2024-02-28
Enrollment: 49
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who were previously evaluated for difficult airway criteria and predicted to have a difficult airway or who could not be ventilated or intubated after induction of anesthesia in another center.

Brief summary: In this study, the investigators will evaluate the advanced airway methods applied in the anesthesiology and reanimation clinic of the hospital to patients who met the criteria for awake intubation specified in the ASA 2022 difficult airway management guideline or who could not be intubated after induction of anesthesia in another center. The advanced airway method applied to the difficult airway patient expected in the operating room, the duration, success and complications of the method will be observed and recorded.

Detailed description: Patients who meet the inclusion criteria will be informed about the difficult airway and their verbal and written consent will be obtained.

When participants are taken to the room, an observer will be in the operation room. There was no emergency to the patient's primary anesthesiologist, will not be involved. Record patients' demographic data, Mallampati scores, thyromental distance, and neck circumference.

The airway method preferred by the physician, procedure duration, number of attempts, success, and complications will be recorded.

Eligibility criteria: Inclusion Criteria:

* Over 18 years old
* Meets the expected difficult airway criteria
* Being awakened after induction of anesthesia in another center
* At least one of the awake intubation criteria in the DAS 2022 guideline
* Elective surgeries

Exclusion Criteria:

* Emergency surgeries
* Patients intubated with anesthesia
* Noncoopere patients

Primary outcomes:
measure: Comparison of advanced airway methods in the awake patient with difficult airway.
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Kocaeli
country: Turkey
facility: Kocaeli City Hospital
Study officials:
affiliation: Kocaeli City Hospital Anesthesiology and Reanimation
name: Mehmet Yilmaz
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01803516: QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
Official title: Quality of Life Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Radiation-Induced Telangiectasias
Keywords: Quality of Life
Assessments
Radiation
Telangiectasias
13-013
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2013-03-04
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients from the Dermatology Division and/or Radiation Oncology, Plastic and Reconstructive Surgery Department(s) and the Breast Cancer Survivorship Program will be identified by the Nurse Practitioners of the survivorship program or by clinicians in these departments for the study.

Brief summary: The purpose of this study is to see how the look of telangiectasias (small dilated blood vessels) on radiated breast skin when altered by the pulsed dye laser affects a patient's overall well being.

Patients will have a set of treatments with a pulsed dye laser. This is a laser that targets red blood vessels and delivers heat causing the telangiectasias to become smaller and less visible. The laser has been used safely to treat telangiectasias on the skin of patients who received radiation for breast cancer.

Patients in the study will be asked to complete a questionnaire asking how they feel about the telangiectasias, their radiated skin and its effect on their daily lives. The questionnaire will be given at every visit. The improvement in the look of patients' radiated skin will also be compared to answers to the questionnaire. We hope the study will improve our understanding of how patients feel about the long term effects of radiation on their skin.


Eligibility criteria: Inclusion Criteria:

* Locally advanced breast cancer patients treated with surgery and adjuvant radiation
* Telangiectasias in the radiation field of the treated breast
* Patients 18 years or older

Exclusion Criteria:

* Non English speaking
* Current oral steroid use or receiving daily therapeutic anticoagulation (e.g. Coumadin, Lovenox)
* Breast/s reconstructed with implant in the area of previous radiation
* Pregnancy or lactation
* Previous laser treatment of telangiectasias
* Presence of a sun tan in the area
* Fitzpatrick skin types V, VI

Primary outcomes:
measure: evaluate quality-of-life (QoL)
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Erica Lee, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06269016: Effect of Hip Strengthening Exercises and Pelvic Floor Exercises on Stress Urinary Incontinence in Postnatal Women
Official title: Effect of Hip Strengthening Exercises and Pelvic Floor Exercises on Stress Urinary Incontinence in Postnatal Women
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Stress Urinary Incontinence
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-02-21
Enrollment: 120
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: this study will investigate effect of hip strengthening exercises and pelvic floor exercises on stress urinary incontinence in postnatal women. Clinical practice guidelines recommend PFMT as the first-line treatment for female SUI . Also, it has been speculated that the hip muscles are involved in the continence mechanism and that their deficiency could destabilize the normal function of the system. The addition of hip muscle exercises, regardless of PFM contractions, aimed to improve muscular condition for the motor or synergic strategies in PFM contraction. Secondary effects of these techniques, such as the influence of passive lumbar rotational mobilization in improving hip flexor strength, have been of high interest in physiotherapy in general


Eligibility criteria: Inclusion Criteria:

1. Their ages will be ranged from 30 to 35 years old.
2. Their BMI will not exceed 35 Kg/m2.
3. All patients will be multipara women.
4. Their deliveries were normal vaginal delivery.
5. All patients will be diagnosed by gynecologist as mild or moderate degree of SUI.
6. All patients will have the same medical treatment and free from any pathological conditions that might affect the result.

Exclusion Criteria:

1. Recurrent urinary tract infections.
2. Hypertension.
3. Diabetes mellitus.
4. Intra uterine device.
5. Hysterectomy.

Primary outcomes:
measure: hip muscles strengthening exercise.
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Mai Mohamed Sherif Mohamed Hassan
Study officials:
References:
Clinical trial NCT06592716: Can Recurrence of Cancer in the Oropharynx Be Detected by Blood Samples?
Official title: Specificity and Sensitivity of Circulating HPV-DNA in Patients with Oropharyngeal Squamous Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Oropharyngeal Squamous Cell Carcinoma (SCC)
Oropharynx Cancer
Oropharynx Cancer, Metastatic
Oropharynx Cancer, Recurrent
Oropharyngeal Carcinoma
Keywords: HPV
HPV-DNA
Liquid biopsy
cell-free HPV-DNA
circulating HPV-DNA
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
Collaborators: name: Copenhagen University Hospital, Denmark
name: Department of Otorhinolaryngology, Head and Neck Surgery and Audiology
First posted: 2024-09-19
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study investigates if longitudinal analyses of cell-free HPV-DNA in blood samples can be utilized to detect recurrence in patients diagnosed and treated for HPV-positive oropharyngeal squamous cell carcinoma.


Eligibility criteria: Inclusion Criteria:

* Patients with newly diagnosed HPV+ (or p16+) OPSCC carcinoma originating from the oropharynx
* Above 18 years of age
* Informed consent
* Patients offered curative treatment.

Exclusion Criteria:

* The patient does not speak or understand Danish
* The patient has another disease/condition considered a reason for exclusion

Primary outcomes:
measure: Sensitivity and specificity of HPV ddPCR
timeFrame: At enrollment and at 2 months, 6 months, 12 months, 18 months, 24 months and 36 months after treatment or at suspicion of recurrence.
Secondary outcomes:
measure: Time to recurrence by HPV-DNA
timeFrame: From enrollment to three years after treatment
measure: Time to recurrence by clinical/radiological examination
timeFrame: From enrollment to three years after treatment
measure: PET/CT
timeFrame: From enrollment to three years after treatment
measure: Cancer fast-track referrals
timeFrame: From enrollment to three years after treatment
measure: Fear of Recurrence Questionnaire
timeFrame: After treatment at 2 months, 6 months, 12 months, 18 months, 24 months and 36 months
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Department of Otorhinolaryngology, Head and Neck Surgery and Audiology
Study officials:
affiliation: Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet
name: Christian von Buchwald, Professor, MD, DMSci
role: STUDY_CHAIR
References:
Clinical trial NCT00905216: Efficacy and Safety of Sodium Heparin in Patients Submitted to Heart Surgery Using Bypass
Official title: Randomized Clinical Trial of Sodium Heparin Effectiveness and Security in Patients Submitted to Heart Surgery Using Bypass
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Cardiac Surgery
Keywords: heparin
Lead sponsor: Azidus Brasil
Sponsor class: INDUSTRY
First posted: 2009-05-20
Enrollment: 104
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The objective of this study is to verify, through a randomized, single-blind, multicentre, parallel and comparative study, the effectiveness of heparin sodium of porcine origin in patients undergoing heart surgery that require the aid of cardiopulmonary bypass. The effectiveness will be determined through the control of hemostasis during and after surgery, based on the strengths of markers of coagulation trichloroacetic acid (TCA), alpha-tocopherol transfer protein (TTPA), Anti-Xa, heparin bioavailability and excessive loss of blood (bleeding) at the end of the surgery.


Eligibility criteria: Inclusion Criteria:

* Patients who agree with all aspects of the study and sign the FICT;
* Patients of both sexes;
* Patients aged above 18 years;
* Patients with cardiac surgery and requiring movement Extracorporeal.

Exclusion Criteria:

* Patients with hematological disorders that compromise the surgical changes (e.g., myeloproliferative syndromes, anemia Hb \< 11.0 g/dL,
* Platelets \< 150,000 mm3);
* Patients with disorders of hemostasis (INR \> 1.40) (rTTPA \> 1.40);
* Patients with renal dysfunction (creatinine \> 1.50);
* Patients with deep hyperthermia;
* Liver disease (AST and ALT \> 2 times that of the reference value);
* Patients with a history of allergy to heparin or protamine;
* Patients with history of heparin-induced thrombocytopenia;
* Tables infection (e.g., endocarditis, infection of immune human (HIV), hepatitis B and C, septicemia and pneumonia);
* Reoperations;
* Use of antiplatelet (clopidogrel and ticlopidine) for less than 7 days;
* Use of acetylsalicylic acid is less than 5 days;
* Use of low molecular weight heparin for less than 24 hours;
* Use of non-fractioned heparin for less than 12 hours.

Primary outcomes:
measure: Comparison of TTPA, Anti-Xa and ACT Comparison of bleeding
timeFrame: Pre - Operative (T0) Pre Heparinization (T1) Top of Extracorporeal (T2) Period Intraoperative (T3) Termination Extracorporeal (T4) Postoperative
Secondary outcomes:
measure: adverse reactions
timeFrame: Pre - Operative (T0) Pre Heparinization (T1) Top of Extracorporeal (T2) Period Intraoperative (T3) Termination Extracorporeal (T4) Postoperative
Other outcomes:
Locations:
city: Valinhos
country: Brazil
facility: Lal Clinica Pesquisa E Desenvolvimento Ltda
state: SP
Study officials:
References:
Clinical trial NCT03454516: Mobility Hypertension Management Study
Official title: Mobility Hypertension Management - Effect of Telemonitoring on Hypertension Management
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hypertension
Keywords: Hypertension
Telemonitoring
Digital Health
Lead sponsor: International Society for Vascular Health
Sponsor class: OTHER
First posted: 2018-03-06
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: two randomized parallel groups. one group with standard care and one group with telemonitoring of blood pressure and hypertension.
Primary purpose: OTHER

Brief summary: The present prospective study aims to assess the efficacy of using the telehealth solution "Hypertension Monitor" in patients with hypertension by comparison to the standard care.

Detailed description: Although, meta-analysis confirms that BP telemonitoring may represent a useful tool to improve hypertension management, the strength of the provided evidence is limited. Therefore, future well-designed, large-sample, prospective, controlled trials are mandatory to understand the benefit of BP telemonitoring.

Recently, a specific telehealth solution for hypertension management has been developed in France (Hypertension Monitor - e-CoreLab®).

The present prospective study aims to assess the efficacy of using the telehealth solution "Hypertension Monitor" in patients with hypertension by comparison to the standard care.

The primary objective: To evaluate whether a home telehealth system can improve BP control and other risk factors in hypertensive individuals, as compared to the standard care.

Eligibility criteria: Inclusion Criteria:

* Men or women
* Age between 18 and 80 years
* Patients with essential moderate Hypertension
* untreated or not adequately treated (need for treatment changes)
* Given written informed consent

Exclusion Criteria:

* Severe Hypertension (\>180/110 mmHg)
* Difficulties to perform home blood pressure measurements
* Patients with arm circumference \> 42 cm
* Night shift workers
* Body mass index \> 35 kg/m²
* Atrial fibrillation and/or another arrhythmia
* Pregnancy
* Cardiovascular events (stroke, Myocardial infarction) in the last 6 months
* Severe Sleep Apnea Syndrome

Primary outcomes:
measure: Systolic Blood Pressure (measured in clinic)
timeFrame: Primary objective after 3 month
Secondary outcomes:
measure: Timing to reach the blood pressure target
timeFrame: Evaluation performed at Month1 and Month 3
Other outcomes:
Locations:
city: Paris
country: France
facility: Roland Asmar
Study officials:
affiliation: Foundation-Medical research Institutes
name: ROLAND ASMAR, MD
role: STUDY_CHAIR
References:
Clinical trial NCT05093816: Evaluating a Single-session Mental Health Intervention for UK University Students
Official title: An Online Wellness Intervention for University Students: Investigating the Efficacy of The Common Elements Toolbox in the UK
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Depression
Anxiety
Happiness
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
Collaborators: name: University of Bath
First posted: 2021-10-26
Enrollment: 700
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators are evaluating if an online single-session intervention, the Common Elements Toolbox (COMET) can improve mental health and wellbeing among UK university students.


Eligibility criteria: Inclusion Criteria:

* At least 18 years old

Exclusion Criteria:

-

Primary outcomes:
measure: Patient Health Questionnaire-9 (PHQ-9)
timeFrame: Change from baseline to four weeks post-intervention
measure: Generalized Anxiety Disorder 7-item Checklist (GAD-7)
timeFrame: Change from baseline to four weeks post-intervention
measure: Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS).
timeFrame: Change from baseline to four weeks post-intervention
measure: Positive and Negative Affect Schedule
timeFrame: Change from baseline to four weeks post-intervention
measure: Acceptability of Intervention Measure (AIM)
timeFrame: Post-intervention (immediately after participants complete the intervention)
measure: Intervention Appropriateness Measure
timeFrame: Post-intervention (immediately after participants complete the intervention)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06936696: Project PAIR: Parent-implemented Articulation Intervention With Recast
Official title: Project PAIR: Parent-implemented Articulation Intervention With Recast
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Hearing Impaired Children
Keywords: deaf and hard of hearing
articulation
speech sound production
parent training
children
Lead sponsor: Vanderbilt University
Sponsor class: OTHER
First posted: 2025-04-20
Enrollment: 10
Sex: ALL
Minimum age (years): 4
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single case multiple baseline across participants
Primary purpose: TREATMENT

Brief summary: Using a single-case multiple baseline across participants design, this study aims to explore the effectiveness of parent-implemented Broad Treatment Speech Recast supplemented with traditional clinician-led articulation therapy on speech production in elementary-aged deaf and hard of hearing children.

To address these objectives, the following research questions will be investigated:

1. Does drill-based articulation therapy, administered by a speech-language pathologist, improve speech sound production in DHH children when parent-implemented BTSR is concurrently utilized at home?
2. Does the combination of parent-implemented BTSR and clinician-led traditional articulation therapy result in generalization of speech sound accuracy at the conversation level?


Eligibility criteria: Inclusion Criteria:

* Age 4;0-9;11
* Permanent, prelingual sensorineural hearing loss
* Uses spoken English as their primary home language (≥ 51% of the time)
* Standard score ≥70 on the Leiter
* Standard score ≥70 on the OWLS-II Listening Comprehension
* At least two speech sound errors appropriate to target based on speech norms and general stimulability

Exclusion Criteria:

* Motor speech disorder (e.g., childhood apraxia of speech)
* Oral structural functional disorder (e.g., cleft palate)
* Diagnosis of autism spectrum disorder
* Diagnosis of ADHD
* Uncorrected vision impairment (i.e., identified vision loss without the use of corrective lenses)

Primary outcomes:
measure: Target phoneme production accuracy
timeFrame: From baseline until end of treatment (when intervention criteria have been reached or 6 weeks of no progress / regression)
Secondary outcomes:
measure: Goldman Fristoe Test of Articulation - Third Edition (GFTA-3)
timeFrame: Collected during eligibility (before the intervention) and at the end of the intervention (when intervention criteria have been reached or 6 weeks of no progress / regression)
measure: Generalization to Conversation
timeFrame: From enrollment to the end of treatment (when child meets criteria or exhibits no progress/regression for three consecutive sessions).
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02447796: Dexmedetomidine and Propofol As Sole Sedative Agent for Patients Undergoing Arteriovenous Fistula Surgery
Official title: A Comparative Study of Dexmedetomidine and Propofol As Sole Sedative Agent for Patients With End-Stage Renal Disease Undergoing Arteriovenous Fistula Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Arteriovenous Fistula
Keywords: (AVF)
surgery
Lead sponsor: Baskent University
Sponsor class: OTHER
First posted: 2015-05-19
Enrollment: 48
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators designed a prospective randomized study to compare the conventionally used sedative drug propofol with a latest alternative dexmedetomidine (DEX), in patients with end-stage renal disease undergoing arteriovenous fistula (AVF) surgery.


Eligibility criteria: Inclusion Criteria:

* Inclusion criteria were patients undergoing arteriovenous fistula (AVF) surgery aged between 20-70 with end stage renal failure on dialysis treatment.

Exclusion Criteria:

* Exclusion criteria were decompensated respiratory or heart failure, liver failure, obesity (body mass index\>30), severe obstructive sleep apnea, need for additional different drugs for sedation, chronic use of alcohol, opioids or other sedative drugs,mental disorders, cognitive disorders, language problems and history of allergy to any medications used in this study.

Primary outcomes:
measure: The incidence of adverse effects such as respiratory and hemodynamic events
timeFrame: up to 24 hours postoperative
Secondary outcomes:
measure: The sedation onset time with using BIS and recovery times during the procedure.
timeFrame: up to 24 hours postoperative
Other outcomes:
Locations:
city: Adana
country: Turkey
facility: Baskent University School of Medicine Adana Research and Teaching Center
Study officials:
affiliation: Baskent University School of Medicine
name: Anis Aribogan, Prof md
role: PRINCIPAL_INVESTIGATOR
References: